Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcγ receptors

Current Opinion in Organ Transplantation

Volumn 16, Issue 1, 2011, Pages 15-20

  Du Clos, Terry W ^a   Mold, Carolyn ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

apoptotic cells; complement; CRP; Fc receptors; PTX3; reperfusion injury; SAP

Indexed keywords

AUTOANTIGEN; C REACTIVE PROTEIN; CELL NUCLEUS ANTIGEN; FC RECEPTOR; FC RECEPTOR IIA; OPSONIN; PENTRAXIN; SERUM AMYLOID P;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; BLOOD VESSEL INJURY; COMPLEMENT ACTIVATION; CRYSTAL STRUCTURE; GRAFT REJECTION; HUMAN; INFLAMMATION; LIGAND BINDING; OPSONIZATION; PROTEIN FUNCTION; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; C-REACTIVE PROTEIN; COMPLEMENT ACTIVATION; HUMANS; ISCHEMIA; MODELS, MOLECULAR; RECEPTORS, IGG; REPERFUSION INJURY; SERUM AMYLOID P-COMPONENT;

EID: 78751633850     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834253c7     Document Type: Article

References (55)

1. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28:157-183.
2. Poon IK, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/ necrotic cell clearance. Cell Death Differ 2010; 17:381-397.
3. Bijl M, Bootsma H, Van Der Geld Y, et al. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004; 63:831-835.
4. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and allcause mortality: the Copenhagen City Heart Study. Eur Heart J 2010; 31:1624-1632.
5. Lu J, Marnell LL, Marjon KD, et al. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 2008; 456:989-992.
6. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999; 7:169-177.
7. Thompson D, Pepys MB, Tickle I, Wood S. The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J Mol Biol 2002; 320:1081-1086.
8. Kushner I, Kaplan MH. Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. J Exp Med 1961; 114:961-974.
9. Du Clos TW, Mold C, Paterson PY, et al. Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol 1981; 43:565-573.
10. Narkates AJ, Volanakis JE. C-reactive protein binding specificities: artificial and natural phospholipid bilayers. Ann N Y Acad Sci 1982; 389:172-182.
11. Hack CE, Wolbink GJ, Schalkwijk C, et al. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 1997; 18:111-115.
12. Ciurana CL, Hack CE. Competitive binding of pentraxins and IgM to newly exposed epitopes on late apoptotic cells. Cell Immunol 2006; 239:14-21.
13. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002; 99:13043-13048.
14. Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem 1984; 259:7311-7316.
15. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1996; 23:253-260.
16. Du Clos TW, Mold C, Stump RF. Identification of a polypeptide sequence that mediates nuclear localization of the acute phase protein C-reactive protein. J Immunol 1990; 145:3869-3875.
17. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112:2135-2147.
18. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42:23-30.
19. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007; 178:3831-3836.
20. Okemefuna AI, Nan R, Miller A, et al. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010; 285:1053-1065.
21. Sjö berg AP, Trouw LA, McGrath FD, et al. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4bbinding protein. J Immunol 2006; 176:7612-7620.
22. Li K, Sacks SH, Zhou W. The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol Immunol 2007; 44:3866-3874.
23. Marnell LL, Mold C, Volzer MA, et al. C-reactive protein binds to FcgRI in transfected COS cells. J Immunol 1995; 155:2185-2193.
24. Bharadwaj D, Stein MP, Volzer M, et al. The major receptor for C-reactive protein on leukocytes is Fcg receptor II. J Exp Med 1999; 190:585-590.
25. Bharadwaj D, Mold C, Markham E, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol 2001; 166:6735-6741.
26. Gaboriaud C, Juanhuix J, Gruez A, et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 2003; 278:46974-46982.
27. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on C-reactive protein. J Immunol 2001; 166:3998-4004.
28. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4:S279-293.
29. Jö nsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcgRIIIa genes. Rheumatology (Oxford) 2007; 46:1417-1421.
30. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13:137-147.
31. Edberg JC, Wu J, Langefeld CD, et al. Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet 2008; 17:1147-1155.
32. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353-1364.
33. Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J Immunol 2009; 182:1397-1403.
34. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A 1997; 94:2575-2580.
35. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with FcgR. J Immunol 2002; 169:7019-7025.
36. Rodriguez W, Mold C, Kataranovski M, et al. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005; 52:642-650.
37. Rodriguez W, Mold C, Marnell LL, et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006; 54:325-335.
38. Szalai AJ, Weaver CT, McCrory MA, et al. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003; 48:1602-1611.
39. Szalai AJ, Nataf S, Hu X-Z, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002; 168:5792-5797.
40. Rodriguez W, Mold C, Kataranovski M, et al. C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcg receptors. J Immunol 2007; 178:530-538.
41. Castano AP, Lin SL, Surowy T, et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009; 1:5ra13.
42. Marsik C, Sunder-Plassmann R, Jilma B, et al. The C-reactive protein ()1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. Clin Chem 2006; 52:1952-1957.
43. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11:328-334.
44. Baldwin WM 3rd, Larsen CP, Fairchild RL. Innate immune responses to transplants: a significant variable with cadaver donors. Immunity 2001; 14:369-376.
45. Wasowska BA. Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol Res 2010; 47:25-44.
46. Nijmeijer R, Lagrand WK, Lubbers YT, et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003; 163:269-275.
47. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 2004; 24:1214-1218.
48. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733-1740.
49. Diaz Padilla N, Bleeker WK, Lubbers Y, et al. Rat C-reactive protein activates the autologous complement system. Immunology 2003; 109: 564-571. (Pubitemid 36930173)
50. Diaz Padilla N, van Vliet AK, Schoots IG, et al. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 2007; 142:722-733.
51. Xing D, Hage FG, Chen YF, et al. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)- dependent. Am J Pathol 2008; 172:22-30.
52. Hage FG, Oparil S, Xing D, et al. C-reactive protein-mediated vascular injury requires complement. Arterioscler Thromb Vasc Biol 2010; 30:1189-1195.
53. Souza DG, Amaral FA, Fagundes CT, et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol 2009; 174:1309-1318.
54. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117:1055-1064.
55. McGregor A, Fox-Talbot K, Velidedeoglu E, et al. The absence of FcgRIII results in increased pro-inflammatory response in FcgRIII KO cardiac allograft recipients. Am J Transpl 2009; 9 (s2):481.